U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
Show Filters
Hide Filters
Development Status
US Approved Rx
1
SHOW MORE...
SHOW LESS
All Match
Any Match
Exclude Selected
Exclude Selected
Clear
Apply
Approval Year
2023
1
SHOW MORE...
SHOW LESS
All Match
Any Match
Exclude Selected
Exclude Selected
Clear
Apply
Substance Class
Nucleic Acid
1
SHOW MORE...
SHOW LESS
All Match
Any Match
Exclude Selected
Exclude Selected
Clear
Apply
Code System
CAS
1
DAILYMED
1
FDA ORPHAN DRUG
1
FDA UNII
1
INN
1
SHOW MORE...
SHOW LESS
All Match
Any Match
Exclude Selected
Exclude Selected
Clear
Apply
Substance Form
Principal Form
1
SHOW MORE...
SHOW LESS
All Match
Any Match
Exclude Selected
Exclude Selected
Clear
Apply
Search results for
"ORPHAN DRUG|Designated|Treatment of transthyretin-mediated amyloidosis"
in
comments
(approximate match)
Showing
1 - 1
of
1
results
Search within data set
First page disabled
Previous page disabled
1
Next page disabled
Next page disabled
Sort By
Approval Year, Recent
Approval Year, Oldest
Relevance
Display Name, A-Z
Display Name, Z-A
Least References
Most References
Oldest Change
Newest Change
EPLONTERSEN
MORE DETAILS
0GRZ0F5XJ6
Export Data
Sequence Search
Status:
US Approved Rx (2023)
First approved in 2023
Class:
NUCLEIC ACID
